Aripiprazole and Metabolite, Serum or Plasma
Also known as: ARIPIPRAZO
Use
The test is used to optimize drug therapy and monitor patient adherence for those under aripiprazole treatment. It quantitatively measures the levels of aripiprazole and its metabolites in serum or plasma to ensure therapeutic levels are achieved and maintained without reaching toxic concentrations. The therapeutic range is primarily based on pre-dose (trough) serum samples collected at a steady-state concentration, helping in adjusting dosages to minimize adverse effects which can include headache, nausea, somnolence, and blurred vision.
Special Instructions
Not provided.
Limitations
This test was developed and its performance characteristics determined by ARUP Laboratories, but it has not been cleared or approved by the US Food and Drug Administration. It is intended for clinical purposes and performed in a CLIA-certified laboratory. Whole blood, gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution) tubes are not acceptable as they may affect the integrity of the measured analytes.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 38893-4 - ARIPiprazole SerPl-mCnc
- 88714-1 - Dehydroaripiprazole SerPl Cfm-mCnc
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection.
Patient Preparation
Pre-dose (trough) draw at steady state concentration.
Storage Instructions
Refrigerated.
Causes for Rejection
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 weeks |
| Refrigerated | 2 weeks |
| Frozen | 2 weeks |
Other tests from different labs that may be relevant